248 related articles for article (PubMed ID: 9384712)
1. Molecular mechanisms of Bcr-Abl-induced oncogenesis.
Gishizky ML
Cytokines Mol Ther; 1996 Dec; 2(4):251-61. PubMed ID: 9384712
[TBL] [Abstract][Full Text] [Related]
2. [Molecular construction of Philadelphia chromosome and its relation to the clinical features].
Kamada N; Tanaka K; Asou H
Gan To Kagaku Ryoho; 1991 Jun; 18(7):1098-105. PubMed ID: 2053768
[TBL] [Abstract][Full Text] [Related]
3. Molecular pathophysiology of chronic myelogenous leukemia.
Turhan AG; Solary E; Vainchenker W; Dusanter-Fourt I
Hematol Cell Ther; 1998 Oct; 40(5):217-21. PubMed ID: 9844814
[TBL] [Abstract][Full Text] [Related]
4. Direct relation between BCR-ABL tyrosine kinase activity and cyclin D2 expression in lymphoblasts.
Deininger MW; Vieira SA; Parada Y; Banerji L; Lam EW; Peters G; Mahon FX; Köhler T; Goldman JM; Melo JV
Cancer Res; 2001 Nov; 61(21):8005-13. PubMed ID: 11691826
[TBL] [Abstract][Full Text] [Related]
5. [Molecular basis of chronic granulocytic leukemia: from test-tube to patient].
Skórski T
Acta Haematol Pol; 1994; 25(2 Suppl 1):184-91. PubMed ID: 8067203
[TBL] [Abstract][Full Text] [Related]
6. Alternative BCR/ABL splice variants in Philadelphia chromosome-positive leukemias result in novel tumor-specific fusion proteins that may represent potential targets for immunotherapy approaches.
Volpe G; Cignetti A; Panuzzo C; Kuka M; Vitaggio K; Brancaccio M; Perrone G; Rinaldi M; Prato G; Fava M; Geuna M; Pautasso M; Casnici C; Signori E; Tonon G; Tarone G; Marelli O; Fazio VM; Saglio G
Cancer Res; 2007 Jun; 67(11):5300-7. PubMed ID: 17545610
[TBL] [Abstract][Full Text] [Related]
7. Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis.
Wilson MB; Schreiner SJ; Choi HJ; Kamens J; Smithgall TE
Oncogene; 2002 Nov; 21(53):8075-88. PubMed ID: 12444544
[TBL] [Abstract][Full Text] [Related]
8. BCR-ABL tyrosine kinase activity regulates the expression of multiple genes implicated in the pathogenesis of chronic myeloid leukemia.
Deininger MW; Vieira S; Mendiola R; Schultheis B; Goldman JM; Melo JV
Cancer Res; 2000 Apr; 60(7):2049-55. PubMed ID: 10766197
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of dual color-dual fusion translocation fluorescence in situ hybridization in the detection of bcr/abl fusion gene.
Wu B; Zhou S; Song L; Liu X
Zhonghua Zhong Liu Za Zhi; 2002 Jul; 24(4):364-6. PubMed ID: 12408765
[TBL] [Abstract][Full Text] [Related]
10. Modeling Philadelphia chromosome positive leukemias.
Wong S; Witte ON
Oncogene; 2001 Sep; 20(40):5644-59. PubMed ID: 11607816
[TBL] [Abstract][Full Text] [Related]
11. ABL oncogenes and phosphoinositide 3-kinase: mechanism of activation and downstream effectors.
Kharas MG; Fruman DA
Cancer Res; 2005 Mar; 65(6):2047-53. PubMed ID: 15781610
[TBL] [Abstract][Full Text] [Related]
12. [The Philadelphia chromosome 30 years later].
Lisker R
Rev Invest Clin; 1992; 44(1):123-30. PubMed ID: 1523343
[TBL] [Abstract][Full Text] [Related]
13. Model mice for BCR/ABL-positive leukemias.
Honda H; Hirai H
Blood Cells Mol Dis; 2001; 27(1):265-78. PubMed ID: 11358387
[TBL] [Abstract][Full Text] [Related]
14. Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148).
Beran M; Cao X; Estrov Z; Jeha S; Jin G; O'Brien S; Talpaz M; Arlinghaus RB; Lydon NB; Kantarjian H
Clin Cancer Res; 1998 Jul; 4(7):1661-72. PubMed ID: 9676840
[TBL] [Abstract][Full Text] [Related]
15. Biology of chronic myelogenous leukemia--signaling pathways of initiation and transformation.
Melo JV; Deininger MW
Hematol Oncol Clin North Am; 2004 Jun; 18(3):545-68, vii-viii. PubMed ID: 15271392
[TBL] [Abstract][Full Text] [Related]
16. Studies of complex Ph translocations in cases with chronic myelogenous leukemia and one with acute lymphoblastic leukemia.
Costa D; Carrió A; Madrigal I; Arias A; Valera A; Colomer D; Aguilar JL; Teixido M; Camós M; Cervantes F; Campo E
Cancer Genet Cytogenet; 2006 Apr; 166(1):89-93. PubMed ID: 16616117
[TBL] [Abstract][Full Text] [Related]
17. Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway.
Kurosu T; Ohki M; Wu N; Kagechika H; Miura O
Cancer Res; 2009 May; 69(9):3927-36. PubMed ID: 19366808
[TBL] [Abstract][Full Text] [Related]
18. Bcr-Abl has a greater intrinsic capacity than v-Abl to induce the neoplastic expansion of myeloid cells.
Gross AW; Ren R
Oncogene; 2000 Dec; 19(54):6286-96. PubMed ID: 11175343
[TBL] [Abstract][Full Text] [Related]
19. BCR/ABL P190 transgenic mice develop leukemia in the absence of Crkl.
Hemmeryckx B; Reichert A; Watanabe M; Kaartinen V; de Jong R; Pattengale PK; Groffen J; Heisterkamp N
Oncogene; 2002 May; 21(20):3225-31. PubMed ID: 12082638
[TBL] [Abstract][Full Text] [Related]
20. Biology of BCR-ABL.
Chopra R; Pu QQ; Elefanty AG
Blood Rev; 1999 Dec; 13(4):211-29. PubMed ID: 10741897
[No Abstract] [Full Text] [Related]
[Next] [New Search]
